Abstract
Although osteosclerotic metastases are characteristic of prostatic carcinoma, bone resorption is also accelerated. Since clodronate inhibits bone resorption and relieves bone pain, we have given it to patients with painful bone disease from prostatic cancer after failure of hormonal therapy. All patients received estramustine phosphate orally. Simultaneously they were randomly allocated to clodronate (36) and placebo (39) groups. Clodronate was given by mouth. The dose was 3.2 g for the first month, thereafter 1.6 g. Pain relief was more distinct in the clodronate group where one third of patients were totally free of bone pain. The use of analgesics stopped in 38% of patients on clodronate and in 18% on placebo which effect probably belongs to estramustine phosphate. Serum calcium concentration decreased more markedly in the clodronate group. Clodronate dose of 3.2 g seemed to be more potent than that of 1.6 g. Side effects were uncommon and occurred equally in both groups. No significant differences were seen in median survival or survival rates between the groups.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Klein, L. A.: Prostatic carcinoma.N. Engl. J. Med., 300, 824 (1979).
Scott, W. W., Menon, M., Walsh, P. C.: Hormonal therapy of prostatic cancer.Cancer, 45, 1929 (1980).
Grayhack, J. T., Keeler, T. C., Kozlowski, J. M.: Carcinoma of the prostate: Hormonal therapy.Cancer, 60, 589 (1987).
Elomaa, I., Kellokumpu-Lehtinen, P., Rannikko, S., Alfthan O.: Hormone resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.Eur. Urol., 19, 12 (1991).
Murphy, G. P., Slack, N. H., Mittelman, T.: Experiences with estramustine phosphate in prostate cancer.Sem. Oncol., 10, 42 (1983).
Kontturi, M., Sotarauta, M., Tammela, T.: Sequentially alternating hormone chemotherapy with high-dose medroxyprogesterone acetate and low-dose epirubicin for treatment of hormone resistant metastatic prostatic cancer.Eur. Urol., 15, 43 (1988).
Fosså, S. D., Jahnsen, J. U., Karlsen, S.: High-dose medroxyprogesterone acetate versus prednisolone in hormone resistant prostatic cancer.Eur. Urol., 11, 11 (1985).
Elomaa, I., Taube, T., Blomqvist, C., Rissanen, P., Rannikko, S., Alfthan, O.: Aminoglutethimide in advanced prostatic cancer resistant to conventional hormonal therapy.Eur. Urol., 14, 104 (1988).
Adami, S., Salvagno, G., Bianchi, G., Dorizzi, R., Rosini, S., Mobilio, G., Lo Cascio, V.: Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.J. Urol., 134, 1152 (1985).
Adami, S., Mian, M.: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma.Recent Results in Cancer Res., 116, 67 (1989).
Lipton, A., Harvey, H., Givant, E., Lipton, N., Lynch, L., Seaman, J., Vandepol, C., Dellanno, D., Zelenakas, K.: Disodium pamidronate (ADP)—a dose seeking study in patients with breast and prostate cancer. In: R. D. Rubens (ed.): Management of Bone Metastases and Hypercalcaemia by Osteoclast Inhibition. Hofgrefe & Huber Publishers, Toronto-Lewiston N. Y.-Bern-Göttingen-Stuttgart 1989, pp. 90–100.
Clarke, N. V., McClure, J., George, J. R.: Subjective and metabolic effects of amino-hydroxypropylidene bisphosphonata (APD) in patients with advanced cancer of the prostate—preliminary report. In: R. D. Rubens (ed.): Management of Bone Metastases and Hypercalcaemia by Osteoclast Inhibition. Hogrefe & Huber Publishers, Toronto-Lewiston N.Y.-Bern-Göttingen-Stuttgart 1989, pp. 81–89.
Schmidt, J. D., Johnson, D. E., Scott, W. W., Gibbons, R. B., Prout, G. R., Murphy, G. P.: The National Prostatic Cancer Project: Chemotherapy of advanced prostatic cancer: evaluation of response parameters.Urology, 7, 602 (1976).
Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A.: Reporting results of cancer treatment.Cancer, 47, 207 (1981).
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento A-L., Selander, K., Lamberg-Allardt, C., Holmström, T.: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.Lancet, 1, 146 (1983).
Ascari, E., Attardo-Parrinello, G., Merlini, G.: Treatment of painful bone lesions and hypercalcemia.Eur. J. Haematol. Suppl. (51),43, 135 (1989).
Urwin, G. H., Percival, R. C., Harris, S., Beneton, M. N. C., Williams, J. L., Kanis, J. A.: Generalized increase in bone resorption in carcinoma of the prostate.Br. J. Urol., 57, 721 (1985).
Percival, R. C., Watson, M. E., Williams, J. L., Kanis, J. A.: Carcinoma of the prostate: remission of paraparesis with inhibitor of bone resorption.Postgrad. Med. J., 61, 551 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elomaa, I., Kylmälä, T., Tammela, T. et al. Effect of oral clodronate on bone pain. International Urology and Nephrology 24, 159–166 (1992). https://doi.org/10.1007/BF02549644
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02549644